Navigation Links
Anastrozole Confirmed Superior in Breast Cancer Prevention
Date:12/14/2007

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated with anastrozole disappears after treatment ends.

Speaking at the Thursday session of the San Antonio Breast Cancer Symposium, Professor John Forbes of the University of Newcastle presented the much-anticipated long-term results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial that compared 5 years of tamoxifen with 5 years of the aromatase inhibitor anastrozole for the treatment of postmenopausal women with invasive breast cancer.

Hormone-responsive breast cancers require estrogen stimulation in order to grow. Tamoxifen, a synthetic variation of estrogen, binds to hormone receptors on hormone-sensitive cancer cells, preventing estrogen from attaching to the cells. Anastrozole, on the other hand, prevents the manufacture of estrogen by body tissues other than the ovaries (e.g., fat cells), so it is useful for the treatment of hormone-sensitive cancers in postmenopausal women whose ovaries are no longer producing estrogen.

Although previous reports at 33 and 68 months demonstrated that anastrozole was more effective, has fewer serious side effects, and was better tolerated than tamoxifen during the period of treatment, it was not known whether the benefits or side effects associated with anastrozole would persist long term after patients were no longer taking the drug.

After 10 years (5 years after the completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrence and metastasis compared with patients who had taken tamoxifen. In fact, the relative benefit of anastrozole actually increased compared with results seen immediately after the completion of treatment.

Most striki
'/>"/>

SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Game Commission Announces EHD Confirmed in Fayette County
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... -- BD Biosciences, a segment of BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... of high-performance research flow cytometers. The BD ... most compact footprint in its class at just 30" x ... (76.2 cm). Recognizing that space is a valuable commodity in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
(Date:6/19/2013)... study led by researchers at The University of Texas ... to show remarkable promise for the treatment of relapsed ... recent interim findings of the 18-center Phase 2 study ... of Medicine . Previous interim findings were presented in ... Annual Meeting and Exposition. , Unprecedented results, ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
(Date:6/19/2013)... A new understanding of the genetic process that ... of potentially dangerous lesions for some women, and also ... therapies in certain cases suggesting they could actually ... The analysis provides a clearer picture of the chromosomal ... papillomavirus sometimes leads to chronic infection and, in less ...
(Date:6/19/2013)... Iowa study reveals significant disparities between minority and ... abuse treatment programs. Moreover, these disparities vary widely ... suggest that for most states there,s something amiss," ... and biostatistics. "There are strong racial and ethnic ... substance abuse treatment programs successfully, and those disparities ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... , His Longevity with the Deadly Disease Inspires ... Sept. 4 When Jerry Lewis takes the stage again on Labor Day ... the same lung disease as he will be watching - and not just ... from the funny man who suffers from a not-so-funny and little known fatal ...
... following is the Labor Day message of Stuart Appelbaum. Appelbaum is president of ... www.rwdsu.org , , NEW YORK, Sept. 4 ... the worst of times and the best of times. , , ... and incompetence our country is now in the midst of its greatest economic ...
... SHENZHEN, China, Sept. 4 /PRNewswire-FirstCall/ - Hard to ... its China based subsidiary Mellow Hope, has just ... Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India. ... for the brain. It helps CNS in multiple ...
... social exclusion, have health problems, study suggests, , FRIDAY, ... considered a depressant, teetotalers as well as heavy drinkers ... than moderate tipplers, a new study has found. , ... don,t drink report having fewer friends than drinkers do, ...
... ... Chain Drug Stores (NACDS) President and Chief Executive Officer Steven C. Anderson, IOM, CAE ... First Circuit ruling on September 3, 2009, upholding the reduction of average wholesale prices ... Alexandria, ...
... SHENYANG, China, Sept. 4 /PRNewswire-Asia/ -- ... wholly-owned subsidiary of China,s,leading IT solutions & services ... its development strategy and new products,officially launching three ... 16 multi-slice CT scanner, Sparkler 1.5T superconductive MRI, ...
Cached Medicine News:Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 2Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 3Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 2Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Non-Drinkers More Likely to Be Anxious, Depressed 2Health News:NACDS: Court Ruling on AWPs Shifts "Urgency for Action" to States 2Health News:Neusoft Announces New Releases of Flagship Medical Products 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... the borders of stereomicroscopy with increase ... high-contrast images and significantly more image ... resolution and contrast. The innovative operating ... all essential functions of a stereomicroscope ...
Medicine Products: